Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Zhejiang Hisun Pharma Invests in US-based Sagent Pharma

publication date: Feb 3, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Zhejiang Hisun Pharmaceutical Co. Ltd. revealed that it will make a $10 million investment in Sagent Pharma, a relatively new company headquartered near Chicago, Illinois. The company will purchase 7 million shares at $1.40 each in privately held Sagent, equivalent to a 4.5% stake. More details...

Stock Symbol: (SHA: 600267)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors